Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 64 results.
User Information
Export Records
  1. 1.   Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas
  2. O'Sullivan Coyne, Geraldine; Kummar, Shivaani; Rubinstein, Larry V; Wilsker,Deborah; Moore, Nancy; Hogu, Murielle; Piekarz, Richard; Covey, Joe; Beumer, Jan H; Ferry-Galow,Katherine; Villaruz, Liza C; Hollingshead,Melinda; Holleran, Julianne L; Deppas, Joshua J; Pommier, Yves; Ko, Brian; Johnson, Barry C; Parchhment, Ralph E; Ivy, Percy; Doroshow, James H; Chen, Alice P
  3. Cancer Chemotherapy and Pharmacology. 2025, May 29; 95(1): 58.
  1. 2.   MYC assembles and stimulates topoisomerases 1 and 2 in a "topoisome"
  2. Das, Subhendu K.; Kuzin, Vladislav; Cameron, Donald P.; Sanford, Suzanne; Jha, Rajiv Kumar; Nie, Zuqin; Rosello, Marta Trullols; Holewinski,Ronald; Andresson,Thorkell; Wisniewski, Jan; Natsume, Toyoaki; Price, David H.; Lewis, Brian A.; Kouzine, Fedor; Levens, David; Baranello, Laura
  3. Molecular Cell. 2022, Jan 6; 82(1): 140-158. e12.
  1. 3.   Effects of substituent pattern on the intracellular target of antiproliferative benzo[b]thiophenyl chromone derivatives
  2. Saito, Yohei; Taniguchi, Yukako; Hirazawa, Sachika; Miura, Yuta; Tsurimoto, Hiroyuki; Nakayoshi, Tomoki; Oda, Akifumi; Hamel,Ernest; Yamashita, Katsumi; Goto, Masuo; Nakagawa-Goto, Kyoko
  3. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2021, OCT 15; 222
  1. 4.   The indenoisoquinoline LMP517: a novel antitumor agent targeting both TOP1 and TOP2
  2. Marzi, Laetitia; Sun, Yilun; Huang, Shar-Yin N; James,Amy; Difilippantonio,Simone; Pommier, Yves
  3. Molecular cancer therapeutics. 2020, AUG; 19(8): 1589-1597.
  1. 5.   Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription
  2. Dalla Rosa, Ilaria; Zhang, Hongliang; Khiati, Salim; Wu, Xiaolin; Pommier, Yves
  3. Journal of Biological Chemistry. 2017, Dec 8; 292(49): 20162-20172.
  1. 6.   Structural genomic changes during mammalian ontogeny: a new dimension
  2. Shiao, Y. H.; Anderson, L. M.
  3. Epigenomics. 2012, Feb; 4(1): 1-4.
  1. 7.   Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
  2. Kummar, S.; Chen, A.; Ji, J. P.; Zhang, Y. P.; Reid, J. M.; Ames, M.; Jia, L.; Weil, M.; Speranza, G.; Murgo, A. J.; Kinders, R.; Wang, L. H.; Parchment, R. E.; Carter, J.; Stotler, H.; Rubinstein, L.; Hollingshead, M.; Melillo, G.; Pommier, Y.; Bonner, W.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Cancer Research. 2011, Sep; 71(17): 5626-5634.
  1. 8.   N-Hydroxyethyl-4-aza-didehydropodophyllotoxin derivatives as potential antitumor agents
  2. Kumar, A.; Kumar, V.; Alegria, A. E.; Malhotra, S. V.
  3. European Journal of Pharmaceutical Sciences. 2011, Sep; 44(1-2): 21-26.
  1. 9.   Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1 alpha in Advanced Solid Tumors
  2. Kummar, S.; Raffeld, M.; Juwara, L.; Horneffer, Y.; Strassberger, A.; Allen, D.; Steinberg, S. M.; Rapisarda, A.; Spencer, S. D.; Figg, W. D.; Chen, X. H.; Turkbey, I. B.; Choyke, P.; Murgo, A. J.; Doroshow, J. H.; Melillo, G.
  3. Clinical Cancer Research. 2011, Aug; 17(15): 5123-5131.
  1. 10.   Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41
  2. Ashkenazi, A.; Viard, M.; Wexler-Cohen, Y.; Blumenthal, R.; Shai, Y.
  3. Faseb Journal. 2011, Jul; 25(7): 2156-2166.
  1. 11.   Histone yH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
  2. Redon, C. E.; Nakamura, A. J.; Zhang, Y. W.; Ji, J. P.; Bonner, W. M.; Kinders, R. J.; Parchment, R. E.; Doroshow, J. H.; Pommier, Y.
  3. Clinical Cancer Research. 2010, Sep; 16(18): 4532-4542.
  1. 12.   Genetic Variants in Nuclear-Encoded Mitochondrial Genes Influence AIDS Progression
  2. Hendrickson, S. L.; Lautenberger, J. A.; Chinn, L. W.; Malasky, M.; Sezgin, E.; Kingsley, L. A.; Goedert, J. J.; Kirk, G. D.; Gomperts, E. D.; Buchbinder, S. P.; Troyer, J. L.; O'Brien, S. J.
  3. Plos One. 2010, Sep; 5(9): 8.
  1. 13.   Proteomic Analysis of Nuclei Isolated from Cancer Cell Lines Treated with Indenoisoquinoline NSC 724998, a Novel Topoisomerase I Inhibitor
  2. Han, B. N.; Stockwin, L. H.; Hancock, C.; Yu, S. X.; Hollingshead, M. G.; Newton, D. L.
  3. Journal of Proteome Research. 2010, Aug 6; 9(8): 4016-4027.
  1. 14.   Polo-box domain: a versatile mediator of polo-like kinase function
  2. Park, J. E.; Soung, N. K.; Johmura, Y.; Kang, Y. H.; Liao, C.; Lee, K. H.; Park, C. H.; Nicklaus, M. C.; Lee, K. S.
  3. Cellular and Molecular Life Sciences. 2010, Jun; 67(12): 1957-1970.
  1. 15.   12 Arylstibonic acids that inhibit the DNA binding of five B-ZIP dimers
  2. Rishi, V.; Oh, W. J.; Heyerdahl, S. L.; Zhao, J. F.; Scudiero, D.; Shoemaker, R. H.; Vinson, C.
  3. Journal of Structural Biology. 2010, May; 170(2): 216-225.
  1. 16.   The DNA binding and 3'-end preferential activity of human tyrosyl-DNA phosphodiesterase
  2. Dexheimer, T. S.; Stephen, A. G.; Fivash, M. J.; Fisher, R. J.; Pommier, Y.
  3. Nucleic Acids Research. 2010, Apr; 38(7): 2444-2452.
  1. 17.   Exon Array Analyses across the NCI-60 Reveal Potential Regulation of TOP1 by Transcription Pausing at Guanosine Quartets in the First Intron
  2. Reinhold, W. C.; Mergny, J. L.; Liu, H. F.; Ryan, M.; Pfister, T. D.; Kinders, R.; Parchment, R.; Doroshow, J.; Weinstein, J. N.; Pommier, Y.
  3. Cancer Research. 2010, Mar; 70(6): 2191-2203.
  1. 18.   Monitoring Drug-Induced gamma H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
  2. Wang, L. H.; Pfister, T. D.; Parchment, R. E.; Kummar, S.; Rubinstein, L.; Evrard, Y. A.; Gutierrez, M. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.; Kinders, R. J.
  3. Clinical Cancer Research. 2010, Feb; 16(3): 1073-1084.
  1. 19.   Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads
  2. Rapisarda, A.; Shoemaker, R. H.; Melillo, G.
  3. Cell Cycle. 2009, Dec; 8(24): 4040-4043.
  1. 20.   4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesufonate) (NSC 88915) and Related Novel Steroid Derivatives as Tyrosyl-DNA Phosphodiesterase (Tdp1) Inhibitors
  2. Dexheimer, T. S.; Gediya, L. K.; Stephen, A. G.; Weidlich, I.; Antony, S.; March, C.; Interthal, H.; Nicklaus, M.; Fisher, R. J.; Njar, V. C.; Pommier, Y.
  3. Journal of Medicinal Chemistry. 2009 52(22): 7122-7131.
  1. 21.   Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
  2. Rapisarda, A.; Hollingshead, M.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Gehrs, B.; Raffeld, M.; Kinders, R. J.; Parchment, R.; Anver, M. R.; Shoemaker, R. H.; Melillo, G.
  3. Molecular Cancer Therapeutics. 2009 8(7): 1867-1877.
  1. 22.   Arylstibonic acids: Novel inhibitors and activators of human topoisomerase IB
  2. Kim, H.; Cardellina, J. H.; Akee, R.; Champoux, J. J.; Stivers, J. T.
  3. Bioorganic Chemistry. 2008 36(4-6): 190-197.
  1. 23.   Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice
  2. Hu, P. Q.; Hurwitz, A. A.; Oppenheim, M. J.
  3. Journal of Rheumatology. 2007, Nov; 34(11): 2243-2252.
  1. 24.   UVC inhibits HIF-1 alpha protein translation by a DNA damage- and topoisomerase I-independent pathway
  2. Rapisarda, A.; Melillo, G.
  3. Oncogene. 2007, Oct; 26(48): 6875-6884.
  1. 25.   Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors
  2. Leupold, J. H.; Yang, H. S.; Colburn, N. H.; Asangani, I.; Post, S.; Allgayer, H.
  3. Oncogene. 2007, Jul; 26(31): 4550-4562.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel